Marco Kevin Malisani

Marco Kevin Malisani has a diverse work experience spanning over several industries. Marco Kevin is currently the Co-founder and Executive Director of Kither Biotech, a biopharma company focused on developing new drug candidates for rare pulmonary diseases. In this role, they secured funding for the clinical development of their lead asset, KIT2014, as an add-on therapy for Cystic Fibrosis, and launched the preclinical development of KITCL27 for Idiopathic Pulmonary Fibrosis.

Prior to this, Malisani co-founded and served as the CEO of Kither Biotech from 2019 to 2022. Marco Kevin also has experience as a Senior Advisor at Compass Banca S.p.A. - Gruppo Mediobanca from 2017 to 2019 and as the COO/Deputy CEO of CreditAccess Asia NV from 2013 to 2016.

Additionally, Malisani has worked as the Lead Investment Manager at DOB Equity, overseeing equity investments in East Africa from 2010 to 2013. Marco Kevin served as the CEO and Director of Investments at Sofia SGR in 2008, and as a Principal at MKI-Ventures from 1999 to 2007.

Earlier in their career, Malisani was an Assistant Director at CVC Capital Partners, evaluating investments in Europe and completing three acquisitions. Marco Kevin also held roles at European Vinyls Corporation, including Corporate Finance and Investor Relations Manager and Strategic Planning Manager. Marco Kevin began their career as an Associate at Goldman Sachs.

Overall, Malisani has a strong background in biopharma, finance, and investment management, with a track record of successfully securing funding and overseeing projects in various industries.

Marco Kevin Malisani attended Harvard University, where they earned their AB degree in Economics. Marco Kevin later pursued further education at INSEAD, where they obtained an MBA degree with a focus on Business Administration and Management.